Eli Lilly and Company vs Novo Nordisk A/S

Full side-by-side comparison — 2026

Data as of May 20, 2026 · Updated automatically

9
LLY Wins
0
Tie
10
NVO Wins

LLY

Price USD 1041.66
P/E Ratio 35.5x
Div Yield 0.0065%
Beta 0.48
Sector Health Care

NVO

Price USD 44.39
P/E Ratio 10.4x
Div Yield 0.0391%
Beta 0.35
Sector Health Care

Price Overview

Metric LLY NVO
Current Price 1041.66 44.39
Previous Close 1018.87 45.07

Valuation

Metric LLY NVO
Trailing P/E 35.51 10.40
Forward P/E 22.53 13.29
Price / Book 28.67 6.21
Price / Sales 12.35 0.61
EV / EBITDA 25.84 1.86

Dividends & Income

Metric LLY NVO
Dividend Yield 0.0065% 0.0391%
Dividend Rate (Annual) 6.46 11.70
5-Year Avg Yield 1.11% 1.45%
Payout Ratio 0.2210% 0.4247%

Risk & Financial Health

Metric LLY NVO
Beta (Volatility) 0.48 0.35
Debt / Equity 139.02 72.09
Quick Ratio 0.72 0.54
Current Ratio 1.50 0.79

Growth & Profitability

Metric LLY NVO
Revenue Growth 0.5550% 0.2400%
Earnings Growth 1.6990% 0.6710%
Return on Equity 1.0746% 0.7140%
Revenue / Share 80.61 73.77
Trailing EPS 28.19 4.30
Forward EPS 44.44 3.37

Analyst Targets

Metric LLY NVO
Analyst Mean Target 1210.00 46.73
Analyst High Target 1500.00 64.21
Analyst Low Target 850.00 39.58

Bottom Line: LLY vs NVO

Novo Nordisk A/S (NVO) leads on 10 of 19 comparable metrics.

Novo Nordisk A/S is the stronger pick for value investors, while Eli Lilly and Company may appeal to growth investors.

Novo Nordisk A/S has a lower Price / Sales (0.60 vs 12.35), which may represent better value per dollar of revenue
Novo Nordisk A/S has a lower EV / EBITDA (1.86 vs 25.84), which may suggest a more attractively priced business
Eli Lilly and Company has a higher Forward EPS (44.44 vs 3.37), which suggests analysts expect higher future earnings per share

This comparison is based on publicly available financial data and is for informational purposes only. It is not investment advice. Past performance does not guarantee future results.

LLY Eli Lilly and Company

Best for Growth Investors
• Higher Revenue Growth: 55.50%
• Higher Earnings Growth: 169.90%
• Higher Return on Equity: 107.46%

NVO Novo Nordisk A/S

Best for Value Investors
• Lower Trailing P/E: 10.40
• Lower Forward P/E: 13.29
• Lower Price / Book: 6.21
Best for Income Investors
• Higher Dividend Yield: 3.91%
• Higher 5-Year Avg Yield: 1.45%

Watch Out

LLY trades at 35.5x earnings vs NVO at 10.4x — a gap this large often reflects different growth expectations, not simple mispricing.

Analyst Upside / Downside

LLY
+16.2%
NVO
+5.3%

Based on analyst mean price targets. Estimates are not guaranteed and may not reflect future performance.

About These Companies

Eli Lilly and Company (LLY)

Health Care · United States · NYQ

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza …

View LLY details →

Novo Nordisk A/S (NVO)

Health Care · Denmark · NYQ

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin …

View NVO details →

Frequently Asked Questions

Which has a better dividend yield, LLY or NVO?
Novo Nordisk A/S currently has the higher dividend yield. Eli Lilly and Company (LLY) yields 0.65% while Novo Nordisk A/S (NVO) yields 3.91%. Past dividends do not guarantee future payments.
Which is more volatile, LLY or NVO?
Eli Lilly and Company is more volatile based on beta. Eli Lilly and Company has a beta of 0.48 and Novo Nordisk A/S has a beta of 0.35. A beta above 1.0 means higher volatility than the overall market.
Which is cheaper by P/E ratio, LLY or NVO?
Novo Nordisk A/S has the lower trailing P/E ratio. Eli Lilly and Company trades at 35.5x earnings while Novo Nordisk A/S trades at 10.4x. A lower P/E may suggest better relative value, but could also reflect lower growth expectations.
Which has more analyst upside, LLY or NVO?
Based on mean analyst price targets, Eli Lilly and Company has more upside potential. Eli Lilly and Company has +16.2% upside and Novo Nordisk A/S has +5.3% upside from current prices. Analyst estimates are not guaranteed.
Can I track both LLY and NVO in one portfolio?
Yes. AllInvestView lets you add both Eli Lilly and Company and Novo Nordisk A/S to the same portfolio and monitor price changes, dividends, total return, and allocation — completely free.

Track LLY and NVO in Your Portfolio

Add both to AllInvestView and compare their real-time performance, dividends, and gain/loss side by side.

Start Free Portfolio

Related Comparisons

Health Care Peers

Stock Pages